ATP Diphosphohydrolase (CD39) Gene Therapy for Inflammatory or Thrombotic Conditions for Transplantation and Means Therefor
    4.
    发明申请
    ATP Diphosphohydrolase (CD39) Gene Therapy for Inflammatory or Thrombotic Conditions for Transplantation and Means Therefor 审中-公开
    ATP二磷酸水解酶(CD39)用于移植的炎症或血栓形成条件的基因治疗及其手段

    公开(公告)号:US20080003212A1

    公开(公告)日:2008-01-03

    申请号:US11562699

    申请日:2007-07-10

    IPC分类号: A61K38/46 A61P7/02

    摘要: A method render endothelial cells capable of inhibiting platelet and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding ecto-ATP diphosphohydrolase or an oxidation-resistant analog thereof, and expressing a protein having functional ecto-ATP diphosphohydrolase activity, such as the human CD39 protein, by said cells under cellular activating conditions. The method, which can be carried out in vivo, ex vivo or in vitro, has use in allogeneic or xenogeneic transplantation as well as to treat systemic or local inflammatory conditions characterized by platelet aggregation leading to thrombus formation.

    摘要翻译: 描述了一种能够抑制血小板和白细胞介导的损伤和炎症的内皮细胞的方法,包括通过插入编码ecto-ATP二磷酸水解酶或其抗氧化类似物的DNA来遗传修饰细胞,并表达具有功能性ecto-ATP二磷酸水解酶 活性,如人类CD39蛋白,由细胞在细胞激活条件下。 可以在体内,离体或体外进行的方法可用于同种异体或异种移植,以及治疗特征在血小板聚集导致血栓形成的全身或局部炎性病症。